Qingdao Haier Biomedical Co Ltd (688139) — Cash Flow-to-Debt Ratio
Qingdao Haier Biomedical Co Ltd (688139) has a Cash Flow-to-Debt Ratio of 0.01x as of June 2023, meaning its operating cash flow of CN¥7.33 Million could theoretically repay 0% of its total liabilities (CN¥1.15 Billion) in one year. Check Qingdao Haier Biomedical Co Ltd total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Qingdao Haier Biomedical Co Ltd Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Qingdao Haier Biomedical Co Ltd across 10 annual periods. Also explore Qingdao Haier Biomedical Co Ltd balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Qingdao Haier Biomedical Co Ltd (2016–2025)
Year-by-year debt coverage analysis for Qingdao Haier Biomedical Co Ltd. For market capitalisation and broader financial context, see Qingdao Haier Biomedical Co Ltd (688139) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.23x | CN¥267.89 Million | CN¥1.17 Billion | ▼ -8.1% |
| 2024 | 0.25x | CN¥291.67 Million | CN¥1.17 Billion | ▲ +8.6% |
| 2023 | 0.23x | CN¥249.26 Million | CN¥1.09 Billion | ▼ -51.3% |
| 2022 | 0.47x | CN¥632.43 Million | CN¥1.34 Billion | ▼ -5.9% |
| 2021 | 0.50x | CN¥632.43 Million | CN¥1.26 Billion | ▼ -16.6% |
| 2020 | 0.60x | CN¥696.62 Million | CN¥1.16 Billion | ▲ +24.6% |
| 2019 | 0.48x | CN¥280.49 Million | CN¥581.08 Million | ▲ +260.9% |
| 2018 | 0.13x | CN¥149.00 Million | CN¥1.11 Billion | ▼ -48.1% |
| 2017 | 0.26x | CN¥148.32 Million | CN¥575.92 Million | ▼ -73.6% |
| 2016 | 0.97x | CN¥220.72 Million | CN¥226.46 Million | — |